Now Playing
Opinion|Videos|April 22, 2024
Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
Author(s)Caitlin Costello, MD, Matthew James Pianko, MD
Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Ralph V. Boccia, MD, FACP, discusses payer models, prior authorization, cost recovery, and patient assistance for bispecifics like teclistamab/daratumumab.
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
Ralph V. Boccia, MD, FACP, details remote monitoring, ICE scoring, CRS prophylaxis, and IVIG strategies for patients receiving bispecifics.
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?
4
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
5